Role of S-Nitrosylation on Beta-Adrenergic Signaling in Cardiac Injury and Repair

S-亚硝基化对 β-肾上腺素能信号传导在心脏损伤和修复中的作用

基本信息

  • 批准号:
    10370376
  • 负责人:
  • 金额:
    $ 70.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

SUMMARY: During the development of heart failure (HF), especially after ischemic injury, derangements in myocardial β- adrenergic receptor (βAR) signaling contribute centrally to pathogenesis, including signal uncoupling and receptor desensitization leading to myocyte death and contractility defects. Waning of signaling through cardiac βARs and other G protein-coupled receptors (GPCRs) is classically regulated via receptor phosphorylation and internalization mediated by GPCR kinases (GRKs) and β-arrestins (β-Arrs). This is significant since the activity of GRK2, which is elevated in myocardium after injury/stress, is pathologic in HF and its inhibition is therapeutic. Through a long-standing collaboration, the Koch and Stamler laboratories have found that GPCRs are regulated by nitric oxide (NO), through S-nitrosylation of cysteine to form protein S-nitrosothiol (SNO), including profound regulation of GRK2 and of β-Arr2. Since cardiac GPCRs, including all three βARs, can activate NO synthase (NOS) enzymes, there is a need to discover how this can promote SNO-mediated cardioprotection, especially downstream of β2- and β3ARs. Our prior work has shown that NO from endothelial NOS (eNOS) inhibits GRK2 by S-nitrosylation at Cys340. Loss of SNO-based regulation in GRK2-C340S mutant knock-in (KI) mice leads to un-checked and enhanced GRK2 activity, and to increased ischemic injury, and to dysfunction during aging. Our labs have also shown that neuronal/inducible NOS (n/iNOS) activity can regulate β-Arr2 through SNO-Cys253 to maintain physiological βAR signaling in the heart. The loss of this SNO-β-Arr2 regulation in β-Arr2-C253S KI mice leads to increased βAR desensitization and HF. Additionally, the Stamler lab recently discovered that β2AR is S-nitrosylated at Cys265 and that this modification regulates β2AR desensitization. Together these data suggest tightly integrated regulation of βAR/GPCR function via receptor-stimulated S-nitrosylation, which plays a central but largely unappreciated role in controlling myocardial function. Our data provides novel insight into consequences of the nitroso-redox imbalance in failing heart. The Central Hypothesis of this Multi-PI proposal is that cardiac βAR signaling and desensitization via GRK2 and β-Arr2 are regulated by S-nitrosylation and that nitroso-redox stress can be understood in terms of altered SNO of receptor, GRK and β-Arr to significantly impair the heart’s response to injury. Specific Aims are: [1] To determine whether GRK2 inhibition via S-nitrosylation plays a mechanistic role in selective βAR responses during cardiac ischemic injury; [2] To determine if β2AR is S-nitrosylated in the ischemic heart and whether this impacts injury and repair; [3] To determine if regulation of β-Arr2 by S-nitrosylation tunes βAR responses during cardiac dysfunction after injury and is integrated with β2AR and GRK2 SNO regulation. Successful completion of these studies will illuminate the role of S-nitrosylation in the integrated adrenergic response to cardiac injury and repair. These fundamental discoveries will reveal new insights into the regulation of cardiac function in health and disease by defining therapeutic interventions to promote cardioprotection, and to serve as a paradigm for signaling systems in other organs and diseases.
总结: 在心力衰竭(HF)的发展过程中,特别是缺血性损伤后,心肌β- 肾上腺素能受体(βAR)信号传导在发病机制中起着重要作用,包括信号解偶联和 受体脱敏导致肌细胞死亡和收缩性缺陷。通过心脏的信号传导减弱 β AR和其他G蛋白偶联受体(GPCR)通常通过受体磷酸化进行调节, 由GPCR激酶(GRKs)和β-抑制蛋白(β-Arrs)介导的内化。这一点很重要,因为活动 GRK 2在损伤/应激后在心肌中升高,在HF中是病理性的,其抑制是治疗性的。 通过长期的合作,科赫和斯塔姆勒实验室发现GPCR受到调控, 通过一氧化氮(NO),通过半胱氨酸的S-亚硝基化形成蛋白质S-亚硝基硫醇(SNO),包括深刻的 GRK 2和β-Arr 2的调节。由于心脏GPCR,包括所有三种β AR,可以激活NO合酶, (NOS)酶,有必要发现这是如何促进SNO介导的心脏保护,特别是 β2-和β 3AR的下游。我们先前的工作表明,来自内皮型一氧化氮合酶(eNOS)的一氧化氮抑制GRK 2 通过Cys 340处的S-亚硝基化。GRK 2-C340 S突变敲入(KI)小鼠中基于SNO的调节的丧失导致 未检查和增强的GRK 2活性,并增加缺血性损伤,以及衰老过程中的功能障碍。我们 实验室还表明,神经元/诱导型NOS(n/iNOS)活性可以通过SNO-Cys 253调节β-Arr 2, 来维持心脏中的生理βAR信号。β-Arr 2-C253 S KI中SNO-β-Arr 2调节的丧失 小鼠导致βAR脱敏和HF增加。此外,Stamler实验室最近发现β2AR 在Cys 265处被S-亚硝基化,并且这种修饰调节β2AR脱敏。这些数据一起 表明βAR/GPCR功能通过受体刺激的S-亚硝基化进行紧密整合调节, 在控制心肌功能中的核心作用,但在很大程度上未被重视。我们的数据提供了新的见解, 亚硝基氧化还原失衡的后果在衰竭的心脏。此Multi-PI提案的中心假设 心脏βAR信号传导和通过GRK 2和β-Arr 2的脱敏受S-亚硝基化调节, 亚硝基氧化还原应激可通过改变受体、GRK和β-Arr的SNO来理解, 心脏对损伤的反应具体目的是:[1]确定GRK 2是否通过S-亚硝基化抑制 在心脏缺血性损伤时,β 2 AR在选择性βAR反应中起机制作用; [2]为了确定β 2 AR是否是 缺血心脏中的S-亚硝基化以及这是否会影响损伤和修复; [3]为了确定是否调节 β-Arr 2通过S-亚硝基化调节损伤后心功能不全时βAR的反应并与β2AR整合 和GRK 2 SNO调节。这些研究的成功完成将阐明S-亚硝基化在 对心脏损伤和修复的综合肾上腺素能反应。这些基本发现将揭示新的 通过定义治疗干预措施, 促进心脏保护,并作为其他器官和疾病中信号系统的范例。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Walter J. Koch其他文献

Activation of LXRα but not LXRβ Protects against Myocardial Ischemia/Reperfusion Injury
激活 LXRα 但不激活 LXRβ 可预防心肌缺血/再灌注损伤
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Erhe Gao;Walter J. Koch;Xin-Liang Ma;Ben He
  • 通讯作者:
    Ben He
Expression of a β-Adrenergic Receptor Kinase Inhibitor Reverses Dysfunction in Failing Cardiomyocytes
  • DOI:
    10.1006/mthe.2001.0508
  • 发表时间:
    2002-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Andrea D. Eckhart;Walter J. Koch
  • 通讯作者:
    Walter J. Koch
Highlights of the 2010 Scientific Sessions of the Heart Failure Society of America, San Diego, California, September 12–15, 2010
  • DOI:
    10.1016/j.cardfail.2010.12.002
  • 发表时间:
    2011-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Christopher M. O’Connor;Walter J. Koch;Douglas L. Mann
  • 通讯作者:
    Douglas L. Mann
Adiponectin inhibits oxidative/nitrative stress during myocardial ischemia reperfusion via PKA signaling
脂联素通过 PKA 信号传导抑制心肌缺血再灌注过程中的氧化/硝化应激
Age-associated Reductions in Cardiac (cid:98) 1 - and (cid:98) 2 -adrenergic Responses Without Changes in Inhibitory G Proteins or Receptor Kinases
与年龄相关的心脏 (cid:98) 1 - 和 (cid:98) 2 - 肾上腺素能反应减少,但抑制性 G 蛋白或受体激酶没有变化
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Rui;E. D. Tomhave;Ding;Xiangwu Ji;M. Boluyt;Heping Cheng;E. Lakatta;Walter J. Koch;NIA.NIH.Gov
  • 通讯作者:
    NIA.NIH.Gov

Walter J. Koch的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Walter J. Koch', 18)}}的其他基金

Role of S-Nitrosylation on Beta-Adrenergic Signaling in Cardiac Injury and Repair
S-亚硝基化对 β-肾上腺素能信号传导在心脏损伤和修复中的作用
  • 批准号:
    10180605
  • 财政年份:
    2021
  • 资助金额:
    $ 70.26万
  • 项目类别:
Role of S-Nitrosylation on Beta-Adrenergic Signaling in Cardiac Injury and Repair
S-亚硝基化对 β-肾上腺素能信号传导在心脏损伤和修复中的作用
  • 批准号:
    10605353
  • 财政年份:
    2021
  • 资助金额:
    $ 70.26万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10612815
  • 财政年份:
    2020
  • 资助金额:
    $ 70.26万
  • 项目类别:
Project 1: Targeting GRK5 in Cardiac Injury and Repair
项目 1:针对心脏损伤和修复中的 GRK5
  • 批准号:
    10612827
  • 财政年份:
    2020
  • 资助金额:
    $ 70.26万
  • 项目类别:
Targeting Pathways Involved in Cardiac Injury for Novel Repair Strategies
针对涉及心脏损伤的途径寻求新的修复策略
  • 批准号:
    10396994
  • 财政年份:
    2020
  • 资助金额:
    $ 70.26万
  • 项目类别:
Targeting Pathways Involved in Cardiac Injury for Novel Repair Strategies
针对涉及心脏损伤的途径寻求新的修复策略
  • 批准号:
    10612814
  • 财政年份:
    2020
  • 资助金额:
    $ 70.26万
  • 项目类别:
Project 1: Targeting GRK5 in Cardiac Injury and Repair
项目 1:针对心脏损伤和修复中的 GRK5
  • 批准号:
    10396998
  • 财政年份:
    2020
  • 资助金额:
    $ 70.26万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10396995
  • 财政年份:
    2020
  • 资助金额:
    $ 70.26万
  • 项目类别:
Annual 2014 Symposium of the AHA Basic Cardiovascular Sciences Council
AHA 基础心血管科学委员会 2014 年年度研讨会
  • 批准号:
    8785442
  • 财政年份:
    2014
  • 资助金额:
    $ 70.26万
  • 项目类别:
Targeting GRK2 (BARK1) in Heart Failure
靶向 GRK2 (BARK1) 治疗心力衰竭
  • 批准号:
    9273272
  • 财政年份:
    2014
  • 资助金额:
    $ 70.26万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了